Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding: 2013-2025

Historic Shares Outstanding for Lineage Cell Therapeutics (LCTX) over the last 10 years, with Sep 2025 value amounting to $230.3 million.

  • Lineage Cell Therapeutics' Shares Outstanding rose 21.97% to $230.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.3 million, marking a year-over-year increase of 21.97%. This contributed to the annual value of $220.4 million for FY2024, which is 25.96% up from last year.
  • Lineage Cell Therapeutics' Shares Outstanding amounted to $230.3 million in Q3 2025, which was up 0.86% from $228.4 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Shares Outstanding ranged from a high of $230.3 million in Q3 2025 and a low of $162.1 million during Q1 2021.
  • Moreover, its 3-year median value for Shares Outstanding was $188.8 million (2024), whereas its average is $197.1 million.
  • Data for Lineage Cell Therapeutics' Shares Outstanding shows a peak YoY rose of 25.96% (in 2024) over the last 5 years.
  • Lineage Cell Therapeutics' Shares Outstanding (Quarterly) stood at $169.5 million in 2021, then grew by 0.36% to $170.1 million in 2022, then grew by 2.88% to $175.0 million in 2023, then grew by 25.96% to $220.4 million in 2024, then rose by 21.97% to $230.3 million in 2025.
  • Its Shares Outstanding stands at $230.3 million for Q3 2025, versus $228.4 million for Q2 2025 and $228.4 million for Q1 2025.